Last reviewed · How we verify
NCT05297383
Combining HIIT and n-3 PUFA Supplementation to Reduce Inflammation and Improve Metabolic Health (HIIT&PUFA)
NA trial testing Omega-3 Polyunsaturated Fatty Acid. in Obesity. Withdrawn.
1 June 2022
Quick facts
| Lead sponsor | Texas Tech University |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | double |
| Primary purpose | treatment |
| Start date | 1 April 2022 |
| Primary completion | 1 June 2022 |
| Estimated completion | 31 December 2022 |
Drugs / interventions tested
- Omega-3 Polyunsaturated Fatty Acid.
- Safflower Oil — full drug profile →
- High-Intensity Interval Training
- Flexibility Training
Conditions studied
- Obesity — all drugs for Obesity →
- Inflammation — all drugs for Inflammation →
- Insulin Resistance — all drugs for Insulin Resistance →
- Dyslipidemias — all drugs for Dyslipidemias →
Sponsor
Texas Tech University
Who can join
Adults 18 to 65, any sex, with Obesity or Inflammation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this pilot study is to understand the combined effects of fish oil and exercise in obesity-associated inflammation acutely. The investigators hypothesize that fish oil will improve gut bacteria profiles, which will in turn potentiate the benefits of an exercise program and reduce inflammation and metabolic risk.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05297383
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Texas Tech University trials
Trials by the same sponsor.
- NCT06755827 — Pilot Testing a Novel Approach to Pediatric Obesity Treatment · Phase 1, PHASE2 · recruiting
- NCT07239609 — ACT for Individuals With MNCD and Their Care Partners · Phase 1 · not yet recruiting
- NCT06919536 — Controlled Feeding With 24 Hour Recall · completed
- NCT06055322 — Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD · NA · recruiting
- NCT06865196 — Investigating a Brief Virtual Seminar Series for Parents of Teens Ages 13-17 · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05297383 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Texas Tech University
- Last refreshed: 11 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05297383.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing